1087 related articles for article (PubMed ID: 23925867)
1. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Bruins Slot KM; Berge E
Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
[TBL] [Abstract][Full Text] [Related]
2. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Bruins Slot KM; Berge E
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD008980. PubMed ID: 29509959
[TBL] [Abstract][Full Text] [Related]
3. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Salazar CA; del Aguila D; Cordova EG
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
[TBL] [Abstract][Full Text] [Related]
6. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.
Aguilar MI; Hart R; Pearce LA
Cochrane Database Syst Rev; 2007 Jul; (3):CD006186. PubMed ID: 17636831
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Bruins Slot KM; Berge E
JAMA; 2014 Mar; 311(11):1150-1. PubMed ID: 24643605
[TBL] [Abstract][Full Text] [Related]
8. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
[No Abstract] [Full Text] [Related]
9. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
[TBL] [Abstract][Full Text] [Related]
10. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.
Li M; Li J; Wang X; Hui X; Wang Q; Xie S; Yan P; Tian J; Li J; Xie P; Yang K; Yao L
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010957. PubMed ID: 37057837
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012169. PubMed ID: 28968483
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
Ruff CT; Giugliano RP; Braunwald E; Hoffman EB; Deenadayalu N; Ezekowitz MD; Camm AJ; Weitz JI; Lewis BS; Parkhomenko A; Yamashita T; Antman EM
Lancet; 2014 Mar; 383(9921):955-62. PubMed ID: 24315724
[TBL] [Abstract][Full Text] [Related]
15. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Aguilar MI; Hart R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001927. PubMed ID: 16034869
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Goodman SG; Wojdyla DM; Piccini JP; White HD; Paolini JF; Nessel CC; Berkowitz SD; Mahaffey KW; Patel MR; Sherwood MW; Becker RC; Halperin JL; Hacke W; Singer DE; Hankey GJ; Breithardt G; Fox KA; Califf RM;
J Am Coll Cardiol; 2014 Mar; 63(9):891-900. PubMed ID: 24315894
[TBL] [Abstract][Full Text] [Related]
17. Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Gandara V; Vazquez F; Gandara E
Vasa; 2016; 45(4):293-8. PubMed ID: 27428497
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
19. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
